Search clinical trials for: BI 201335 (Reference)

Total 2119 results

Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers, Including Investigation of the Effect of Food on the Bioavailability of BI 1181181

Healthy

Germany
UCSF Benioff Children's Hospital Oakland
Almond Board of California

Completed

Effects of Almond Intake on Atherogenic Lipoprotein Particles

Dyslipidemia | Obesity, Abdominal

United States
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 1015550 is Taken up and Handled by the Body

Healthy

Netherlands
Boehringer Ingelheim

Not yet recruiting

A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity

Obesity
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1021958 in Otherwise Healthy Controlled Asthmatic Subjects

Healthy | Asthma

Germany
Fundación Cardiovascular de Colombia

Completed

Continuous Supraglottic Aspiration in Intubated and Mechanically Ventilated Patients: the "SUPRAtube" Device (Supratube)

Aspiration Pneumonias

Colombia
National Research Centre for the Working Environment...
University of Southampton; University of Southern Denmark

Completed

Implementation of Physical Exercise at the Workplace (IRMA09) - Laboratory Technicians (IRMA)

Stress | Musculoskeletal Disorders

Denmark
Almirall, S.A.
Sciderm GmbH

Completed

Exploratory Study to Investigate Efficacy of LAS41004 in a Psoriasis Plaque Test

Psoriasis

Germany
Asir John Samuel
Maharishi Markandeshwar International School, Mullana

Completed

Normative Reference Values of Equilibrium Coordination Test Among Children

Coordination Disorder, Developmental

India
Institut fur Diabetes Karlsburg GmbH

Completed

User Evaluation of BGM VGM77

Diabetes

Germany
National Research Centre for the Working Environment...
University of Southampton

Completed

Implementation of Physical Exercise at the Workplace (IRMA10) - Occupational Load (IRMA10)

Stress | Musculoskeletal Disorders

Denmark
National Research Centre for the Working Environment...
University of Southern Denmark

Completed

Work Place Adjusted Intelligent Physical Exercise Reducing Musculoskeletal Pain in Shoulder and Neck (VIMS) - Shoulder Function (VIMS03)

Neck Pain | Shoulder Pain | Rehabilitation | Scapular Dyskinesis | Muscle Activation

Denmark
Boehringer Ingelheim

Completed

A Study in Healthy Men to Measure the Amount of BI 730357 in the Blood When Taken as a Tablet

Healthy

Netherlands
Boehringer Ingelheim

Completed

This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.

Neoplasms | Carcinoma, Non-Small-Cell Lung

United States, Spain, United Kingdom, Canada, Poland
Boehringer Ingelheim

Terminated

A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread

Neoplasms | Carcinoma, Non-Small-Cell Lung | Neoplasm Metastasis

United States
Boehringer Ingelheim

Completed

Single Rising Dose Study With Intravenous Infusion and Subcutaneous Injection of BI 1005273 in Healthy Male Volunteers.

Healthy

Germany
Boehringer Ingelheim

Completed

A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS])

Solid Tumors, KRAS Mutation

Japan
Boehringer Ingelheim

Completed

A Study to Test Different Doses of BI 765063 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer (Solid Tumors)

Solid Tumors

Japan
Boehringer Ingelheim

Completed

Drug-drug Interaction of BI 201335 and Microgynon

Hepatitis C, Chronic

Germany
Boehringer Ingelheim

Recruiting

A Study in Healthy Men to Test How Different Doses of BI 3031185 Are Tolerated and How Food Influences the Amount of BI 3031185 in the Blood

Healthy

Germany
Boehringer Ingelheim

Recruiting

IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack (IRI-EXPLORE)

Myocardial Infarction

Korea, Republic of, Germany, Spain, Hungary, United Kingdom, Italy, Canada, Australia, Poland, Slovakia, New Zealand
Boehringer Ingelheim

Recruiting

A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer

Neuroendocrine Neoplasms | Small Cell Lung Carcinoma (SCLC)

Netherlands
Boehringer Ingelheim

Completed

A Study in Healthy People to Compare 2 Different Formulations of BI 1015550 Taken With or Without Food

Healthy

Germany
Boehringer Ingelheim

Terminated

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of Single Escalating Doses of BI 1034020 Administered Intravenously or Subcutaneously to Male Healthy Volunteers

Healthy

Germany
Clinical Nutrition Research Centre, Singapore
Barilla Singapore Pte Ltd

Completed

Glycemic and Insulinemic Response of Pasta Products in Comparison to Asian Foods

Diabetes

Singapore
Boehringer Ingelheim

Completed

Multiple Rising Oral Doses of BI 1060469 in Healthy Subjects and Mild Asthma Patients

Asthma

Germany
JW Pharmaceutical

Completed

To Evaluate the PK, PD, Safety and Drug Tolerance in Healthy Volunteers

Healthy

Korea, Republic of
Boehringer Ingelheim

Recruiting

A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6

Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Lung Cancer | Gastrointestinal Cancer | Liver Cancer

Japan
Boehringer Ingelheim

Active, not recruiting

A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours

Neoplasms | Non-squamous, Non-Small-Cell Lung Cancer

United States, Spain, Korea, Republic of, France, Hong Kong, United Kingdom, Germany, Australia, Taiwan, Poland, Russian Federation, Ukraine
Boehringer Ingelheim

Completed

Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia

Schizophrenia

Spain, Korea, Republic of, United Kingdom, Taiwan, United States, Austria, Italy, Germany, Poland, Japan, Canada
Assistance Publique - Hôpitaux de Paris

Recruiting

Do Patients Want to Engage in Discussions Dedicated to Anticipating (DDA) Their Preferences of Care in the Event of Worsening Health Status? (ESOP)

Neoplasm Metastasis | Advanced Cancer | Locoregional Neoplasm

France
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test if Different Formulations of BI 764198 With or Without Food Influence the Amount of BI 764198 in the Blood

Healthy

Belgium
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 691751 in Healthy Asian Male Volunteers

Healthy

Korea, Republic of
University of Oxford

Completed

Studying Movement Control in Parkinson's Disease Using Closed Loop Deep Brain Stimulation

Parkinson Disease

United Kingdom
Eli Lilly and Company

Completed

A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices

Healthy

United States
Lund University

Completed

Effects of Whole Grain Rye on Metabolic Risk Markers and Mood

Metabolic Disorders and Cognitive Decline
Leo Wang
West China Hospital

Completed

Clinical Trial of Transtek Body Fat Analyzer (GBF-835-N2 & Other 7 Models) (15001Analy)

Weight | Body Fat Disorder

China
University Hospital, Grenoble

Completed

a Randomized Multicenter Trial Comparing Vacuum Assisted Delivery With the New Device "iCUP" Versus the Reference Cup. (ICUP)

Randomized Controlled Trials | Vacuum Extraction, Obstetrical | Failures, Medical Device | Maternal Lesions | Neonatal Lesions

France
Boehringer Ingelheim

Recruiting

A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)

Solid Tumors

Spain, Japan, United Kingdom, United States
Boehringer Ingelheim

Completed

A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)

Neoplasms

Spain, United States, United Kingdom
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 1291583 is Taken up by the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

A Study to Test How Healthy Women Tolerate Different Doses of BI 1819479

Healthy

Germany
Boehringer Ingelheim

Completed

Assessment of the Handling Experience With the BI 695501 Autoinjector in Patients With Rheumatoid Arthritis Followed by an Extension Phase Using BI 695501 Prefilled Syringe

Arthritis, Rheumatoid

United States, Poland
Boehringer Ingelheim

Active, not recruiting

A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)

Neoplasms

Spain, United States, Belgium, Germany, Netherlands, Australia, France, Japan, United Kingdom, Singapore, Hungary
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Different Doses of BI 474121 Are Taken up and How They Influence the Amount of a Molecular Messenger (cGMP) in the Spinal Fluid

Healthy

Netherlands
Boehringer Ingelheim

Completed

This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is

Psoriasis

United States, Canada, Germany
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Healthy Men and People With Overweight or Obesity

Healthy

Germany
Boehringer Ingelheim

Recruiting

A Study to Test How Well Multiple Doses of BI 765423 Are Tolerated by Healthy Men

Healthy

Belgium
Boehringer Ingelheim

Recruiting

A Study in Healthy Men to Test How Well Different Doses of BI 3802876 Are Tolerated

Healthy

Belgium
Boehringer Ingelheim

Active, not recruiting

A Study in Healthy People to Test How Well Repeated Doses of BI 3032950 Are Tolerated

Healthy

Belgium

3

Subscribe